Search alternatives:
significant base » significant based (Expand Search), significant cause (Expand Search), significant bias (Expand Search)
degs decrease » mean decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
base case » use case (Expand Search)
significant base » significant based (Expand Search), significant cause (Expand Search), significant bias (Expand Search)
degs decrease » mean decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
base case » use case (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
Base-case analysis.
Published 2025“…At a CET of 0.51 times GDP per capita (US$6,394.536), the base-case analysis showed that the incremental costs of AOM relative to PP1M after 10 years of treatment were US$1,926.373 with an incremental gain of 0.306 QALYs. …”
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
The base case analysis.
Published 2025“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”
-
20
Base-case results.
Published 2025“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”